<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>83</volume><submitter>Zhang C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver pathologies. However, no medical treatment has been approved for the treatment of NAFLD. In our previous study, we found that PKLR could be a potential target for treatment of NALFD. Here, we investigated the effect of PKLR in in vivo model and performed drug repositioning to identify a drug candidate for treatment of NAFLD.&lt;h4>Methods&lt;/h4>Tissue samples from liver, muscle, white adipose and heart were obtained from control and PKLR knockout mice fed with chow and high sucrose diets. Lipidomics as well as transcriptomics analyses were conducted using these tissue samples. In addition, a computational drug repositioning analysis was performed and drug candidates were identified. The drug candid</pubmed_abstract><journal>EBioMedicine</journal><pagination>104214</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9420484</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning.</pubmed_title><pmcid>PMC9420484</pmcid><pubmed_authors>Yang H</pubmed_authors><pubmed_authors>Turkez H</pubmed_authors><pubmed_authors>Shi M</pubmed_authors><pubmed_authors>Boren J</pubmed_authors><pubmed_authors>Uhlen M</pubmed_authors><pubmed_authors>Yıldırım S</pubmed_authors><pubmed_authors>Sebhaoui J</pubmed_authors><pubmed_authors>Wei Y</pubmed_authors><pubmed_authors>Shi X</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Kim W</pubmed_authors><pubmed_authors>Klevstig M</pubmed_authors><pubmed_authors>Tozlu OO</pubmed_authors><pubmed_authors>Hacımuftuoglu A</pubmed_authors><pubmed_authors>Iqbal S</pubmed_authors><pubmed_authors>Arif M</pubmed_authors><pubmed_authors>Mardinoglu A</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Nielsen J</pubmed_authors><pubmed_authors>Bayram C</pubmed_authors><pubmed_authors>Bolat I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning.</name><description>&lt;h4>Background&lt;/h4>Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver pathologies. However, no medical treatment has been approved for the treatment of NAFLD. In our previous study, we found that PKLR could be a potential target for treatment of NALFD. Here, we investigated the effect of PKLR in in vivo model and performed drug repositioning to identify a drug candidate for treatment of NAFLD.&lt;h4>Methods&lt;/h4>Tissue samples from liver, muscle, white adipose and heart were obtained from control and PKLR knockout mice fed with chow and high sucrose diets. Lipidomics as well as transcriptomics analyses were conducted using these tissue samples. In addition, a computational drug repositioning analysis was performed and drug candidates were identified. The drug candid</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2026-05-27T11:27:02.744Z</modification><creation>2025-04-21T14:47:39.844Z</creation></dates><accession>S-EPMC9420484</accession><cross_references><pubmed>35988463</pubmed><doi>10.1016/j.ebiom.2022.104214</doi></cross_references></HashMap>